Search results: Sage Journals

Restricted accessReview articleFirst published October, 2019

The emergence of follow-on disease-modifying therapies for multiple sclerosis

Brandon P Moss, Jeffrey A Cohen

Multiple Sclerosis Journal

Open accessReview articleFirst published 2021

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Heinz Wiendl, Ralf Gold, Thomas Berger [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published July, 2018

The effect of disease modifying therapies on CD62L expression in multiple sclerosis

Margarete Maria Voortman, Paul Greiner, Daniel Moser [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessReview articleFirst published 2021

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Daniel M. Hartung

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published October, 2020

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies

Marisa P McGinley, Philip A Cola, Robert J Fox [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2016

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice

Erin E Longbrake, Anne H Cross, Amber Salter

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessResearch articleFirst published 2021

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age

Yinan Zhang, Amber Salter, Shan Jin [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published June, 2013

Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis

Bruce AC Cree

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2021

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis

Gisela Zanga, Estefania Drzewiscki, Paula Tagliani [...]

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published December, 2009

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

Roisín Lonergan, Katie Kinsella, Marguerite Duggan [...]

Multiple Sclerosis Journal

Restricted accessReview articleFirst published October, 2019

The emergence of follow-on disease-modifying therapies for multiple sclerosis

Brandon P Moss, Jeffrey A Cohen

Multiple Sclerosis Journal

Open accessReview articleFirst published 2021

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Heinz Wiendl, Ralf Gold, Thomas Berger [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published July, 2018

The effect of disease modifying therapies on CD62L expression in multiple sclerosis

Margarete Maria Voortman, Paul Greiner, Daniel Moser [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessReview articleFirst published 2021

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Daniel M. Hartung

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published October, 2020

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies

Marisa P McGinley, Philip A Cola, Robert J Fox [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2016

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice

Erin E Longbrake, Anne H Cross, Amber Salter

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessResearch articleFirst published 2021

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age

Yinan Zhang, Amber Salter, Shan Jin [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published June, 2013

Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis

Bruce AC Cree

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2021

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis

Gisela Zanga, Estefania Drzewiscki, Paula Tagliani [...]

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published December, 2009

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

Roisín Lonergan, Katie Kinsella, Marguerite Duggan [...]

Multiple Sclerosis Journal